Skandinaviska Enskilda Banken AB publ Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Skandinaviska Enskilda Banken AB publ lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 131,592 shares of the medical research company’s stock after selling 19,336 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.07% of IQVIA worth $25,983,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Impax Asset Management Group plc grew its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares during the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Covestor Ltd boosted its stake in shares of IQVIA by 34.4% during the third quarter. Covestor Ltd now owns 246 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 63 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in IQVIA during the 3rd quarter worth about $57,000. Finally, Apollon Wealth Management LLC raised its stake in IQVIA by 9.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock valued at $1,155,000 after purchasing an additional 427 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on IQV. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley raised their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Down 2.1 %

NYSE:IQV opened at $181.53 on Friday. The firm has a market capitalization of $32.01 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $256.76. The business’s 50-day moving average is $196.87 and its two-hundred day moving average is $211.38. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.